Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1172199 | 0.88 | CHRNA7 (0.69) | CHRNA7PSMB5KCNA3PSMB1 | |
| Bromide SCHEMBL4827485 | 0.86 | CHRNA7 (0.69) | CHRNA7PSMB5KCNA3PSMB1 | |
| Bromide SCHEMBL1171472 | 0.86 | CHRNA7 (0.69) | CHRNA7PSMB5KCNA3PSMB1 | |
| Bromide SCHEMBL4827422 | 0.83 | CHRNA7 (0.68) | CHRNA7KCNA3 | |
| Bromide SCHEMBL10362108 | 0.82 | CHRNA7 (0.53) | CHRNA7KCNA3 | |
| Bromide SCHEMBL30875781 | 0.80 | CHRNA7 (0.72) | CHRNA7PSMB5KCNA3PSMB1 | |
| Bromide SCHEMBL30875784 | 0.80 | CHRNA7 (0.72) | CHRNA7PSMB5KCNA3PSMB1 | |
| Bromide SCHEMBL28435573 | 0.80 | CHRNA7 (0.72) | CHRNA7PSMB5PSMB1 | |
| Bromide SCHEMBL9442320 | 0.80 | CHRNA7 (0.44) | CHRNA7 | |
| Bromide SCHEMBL3237506 | 0.79 | L3MBTL1 (0.53) | CHRNA7CYP1A2CYP2D6CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CHRNA7 2588/4885PSMB5 2809/4885KCNA3 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.